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ABSTRACT  
 
Background 
In Africa, infective endocarditis (IE) is still a disease of young adults with underlying 
rheumatic heart disease (RHD). As of 2006, almost two-thirds of all persons infected 
with human immunodeficiency virus (HIV) are living in sub-Saharan Africa. Southern 
Africa thus remains the epicentre of the global HIV epidemic. The HIV sero-prevalence 
data reported in Southern Africa are as high as 20% - 30% of the adult population aged 
between 15 and 49 years. In South Africa, the prevalence of HIV among adults aged 15 - 
49 is 18.8%. Based on a simple extrapolation, there is a higher possibility of encountering 
a significant number of patients infected with HIV and underlying RHD with IE in 
Southern Africa than in any other part of the world. In Africa because both HIV and 
valvular heart disease are relatively common, the co-existence of the two conditions in 
individual patients is not rare.    
 
 
Despite the major advances in diagnosis and management of this classical disease, the 
overall mortality rates for both native-valve and prosthetic-valve endocarditis remain as 
high as 20 to 25 percent after 1 year and at 50% after 10 years. However, the mortality 
rate varies, depending on a number of factors, such as:  
• the causative microorganism 
• the presence of complications 
• the development of perivalvular extension or a myocardial abscess 
• neurological events 
• the existence of conditions such as congestive heart failure 
• renal failure 
• severe immunosuppression due to HIV infection in intravenous drug abusers 
• the use of combined medical therapy and surgical therapy in appropriate patients. 
 
 vi
The clinical outcome of infective endocarditis in HIV patients is poor, severe 
immunodeficiency in IVDAs with IE has been reported to be associated with poor 
outcome. However, such an association has never been documented in non-IVDAs, 
particularly in Africa, where the expected majority patients with HIV and IE are non-
IVDAs.  
 
The clinical profile including bacteriology of infective endocarditis in HIV patients is 
different from HIV uninfected patients. The clinical impact of the HIV epidemic on 
infective endocarditis in Africa has not been elucidated in the world literature and there 
is, moreover, a paucity of literature describing this clinical entity of HIV and IE in Africa.   
 
Objective 
The objective of this study was to highlight the co-existence of infective endocarditis in 
HIV positive, non-intravenous drug abuse in South Africa and Africa by: reporting three 
cases admitted at the researcher’s institution within a period of two months; and 
undertaking a literature review.    
 
Methods 
This was a retrospective case report and literature review study of IE in HIV infected 
patients. Three HIV positive patients with IE and with or without underlying chronic 
rheumatic heart disease were reported. The patients were admitted at the researcher’s 
institution within a period of two months. All three patients did not report intravenous 
drug abuse. However, all patients died within a short period of admission to the hospital.     
 
The systematic review of cases published in the literature was delivered from MEDLINE 
SEARCH from January 1985 to December 2006. The following key words were used: 
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, 
Rheumatic Heart Disease, Infective Endocarditis, and Intravenous Drug Abusers 
and Non-Intravenous Drug Abusers. Most of the articles were identified in English; 
where articles were identified in Spanish and French, only abstracts were used.    
 vii
Literature emanating from Africa was emphasized.  In addition, the references quoted in 
this study were reviewed for relevance on the topic. 
Results 
Three patients with definitive IE and infected with HIV were reported: one patient was 
without underlying chronic rheumatic valvular heart disease and two showed underlying 
chronic rheumatic valvular heart disease. There are few reported studies of IE not related 
to intravenous drug abuse in HIV infected patients in the literature, which is probably 
attributable to the reported low prevalence of IE in this sub-group of patients. Most of 
these published studies are limited to a series of case reports and very little data or reports 
originate from Africa.  
  
Conclusion 
The clinical pattern of IE in HIV positive patients who are not IVDAs is not well 
described in literature. However, in this anecdotal case report, the three patients studied 
retrospectively had a poor outcome. Based on this anecdotal report of three cases 
described, if an extrapolation was done from these numbers and a prospective analysis 
performed, we would observed a substantial number of non-IVDU cases with infective 
endocarditis and HIV/AIDS in Africa. The literature review in its current form may shed 
some light on HIV and IE in non-IVDU patients, but doesn’t specifically address the 
issue of the potential co-existence of HIV and IE in Africa.  Given the high prevalence 
both HIV/AIDS and rheumatic valvular heart disease in Africa, in future, we are more 
likely to see a significant proportion of patients with IE and underlying rheumatic 
valvular heart disease who are coincidentally HIV infected. There is a useful need for 
prospective studies describing the prevalence and outcome and for subsequently defining 
the management of this condition in Africa. 
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CHAPTER ONE 
 
1.1 BACKGROUND 
In the last half century we have seen major changes in the epidemiology, bacteriology 
and clinical presentation of infective endocarditis in developed countries, where the 
incidence and prevalence of acute rheumatic fever and its subsequent long term 
complication, rheumatic heart disease, has significantly declined. These changes 
observed in the patient profiles and clinical presentations of infective endorcarditis in the 
developed world have been highlighted extensively in the literature.¹ ⁻ ⁷, ¹⁵, ¹⁶, ¹⁸, ¹⁹ In 
Africa and other developing countries, where acute rheumatic fever still is prevalent, 
infective endocarditis is still a disease of young adults with underlying rheumatic heart 
disease. ¹ ⁻ ¹⁴, ¹⁷  
 
1.1.1 Rheumatic Heart Disease and Infective Endocarditis in Africa (sub-
Saharan Africa) and South Africa 
According to WHO (2004), at least 15·6 million people worldwide had RHD. The 
prevalence of RHD is highest in sub-Saharan Africa and is estimated to be 5·7 per 1000 
in children aged 5 – 14 years.⁶, ⁷ This prevalence has been estimated mainly from surveys 
of school-going children and varies from 2.7/1000 in Kenya (Nairobi) ⁸, Zambia 
(Lusaka)12.5/1000⁹, Ethiopia (Addis Ababa) 6.4/1000¹⁰, Republic of Guinea (Conakry)  
3.9/1000¹¹ to  14.3/1000 in Democratic Republic of Congo (Kinshasa).¹² In a survey of 
12, 050 black school children in Soweto, South Africa, in 1975, McLaren et al. found a 
prevalence of 6.9/1000, with a maximum of 20/1000 in seventh and eighth-grade 
children.⁶, ¹³ The prevalence of RHD increases with age, peaking in adults aged 25 – 34 
years.⁶, ⁷ 
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In Africa and other developing countries, infective endocarditis remains a disease of 
young adults with underlying rheumatic heart disease; unlike in the developed world, 
where the prevalence has shifted towards older patients with degenerative heart disease 
and other co-morbid risk factors.¹ ⁻ ¹⁹  
 
Keogelenberg et al.¹ (2003) reported that in the Western Cape, in South Africa, as in 
other developing countries, infective endocarditis is a disease of younger adults, with 
rheumatic heart disease being the major predisposing factor and that degenerative heart 
disease and intravenous drug abuse are not important risk factors. 
 
Despite improvements in diagnostic accuracy, medical therapy and surgical techniques, 
the mortality remains high. The overall mortality rates for both native-valve and 
prosthetic-valve endocarditis remain as high as 20% to 25% after 1 year and at 50% after 
10 years. However, the mortality rate varies depending on the number of factors 
associated with patients, including: the causative micro-organism, the presence of 
complications, the development of perivalvular extension or a myocardial abscess, 
neurological events or the existence of conditions such as congestive heart failure, renal 
failure, severe immunosuppresion due to HIV infection in intravenous drug abusers, and 
the use of combined medical therapy and surgical therapy.² , ⁴, ⁵, ¹⁹, ²º, ²¹ Although severe 
immunodeficiency in IVDAs with IE has been reported to be associated with poor 
outcome,²⁷, ²⁹, ³¹ ⁻ ³⁷  such a relationship has not been documented in non-IVDAs, 
particularly in Africa, where the expected majority of patients with HIV and IE are non-
IVDAs.  
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1.1.2  HIV/AIDS in Africa (sub-Saharan Africa) and South Africa 
In 2006, almost two thirds (63%) of all persons infected with HIV were living in sub-
Saharan Africa. The number was estimated to be 24.7million; [21.8 million – 27.7 
million]. An estimated 2.8 million [2.4 million – 3.2 million] sub-Saharan adults and 
children became infected with HIV in 2006, more than in all other regions of the world 
combined.²³ Southern Africa remains the epicentre of the global HIV epidemic: 32% of 
people with HIV globally live in this sub-region and 34% of AIDS deaths globally 
occurred here.²³, ²⁴ The sero prevalence data reported in Southern Africa is as high as 
20% - 30% of the adult population aged between 15-49.²³, ²⁴ 
  
South Africa is the country with the largest number of HIV infections in the world, 
estimated at a total 5.7 – 6.7 million, comprising 3.07 – 3.6 million females and 2.6 – 3.1 
million men. The epidemic varies considerably between provinces, from 15% in the 
Western Cape to 39% in the province of KwaZulu-Natal, with a national prevalence rate 
of about 29%.²³, ²⁴ 
 
1.1.3  Infective Endocarditis in HIV positive, non-IVDAs in South Africa and 
Sub- Saharan Africa  
There is limited published data available for infective endocarditis in HIV positive 
individuals in South Africa and other sub-Saharan Africa countries, despite the high 
prevalence of HIV/AIDS and rheumatic heart disease being a major predisposing risk 
factor for IE in this region. Koegelenberg  et al.¹ (2003) established in Cape Town that 
HIV infection is not an independent risk factor for IE:  the authors assert that given the 
high prevalence of both HIV and rheumatic valvular heart disease, future prospective 
studies may find that a significant proportion of patients with infective endocarditis and 
underlying rheumatic valvular disease are coincidentally HIV infected. In Africa because 
both HIV and valvular heart disease are relatively common, the co-existence of the two 
conditions in individual patients is not rare.    
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Based on this hypothesis, the author postulated a relationship between HIV and IE in 
Sub-Saharan Africa, as shown in Figure 1 below. 
 
 
 
 
Figure 1: The postulated epidemiological and demographic similarities between           
HIV/AIDS and infective endocarditis in Africa 
 
 
HIV/AIDS:  
Sub-Saharan Africa: 63% of world 
cases. 
SA (2004) rate: 29.5% 
Total: 5.7 – 6.7 million  
Female: 3.07 – 3.6 million 
Male 2.6 – 3.07 million 
RHD:  
Survey studies reported prevalence 
2.7/1000 to 20/1000 person per 
year. 
Estimated risk factor for IE is up to 
76%. 
 
 
 
 
       Age 15 – 49 
Significant number of IE 
with RHD 
Significant number 
HIV/AIDS with 
Rheumatic Valvular 
Disease 
Significant number of 
IE patients infected 
with HIV / AIDS  
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1.1.4  Clinical Profile of infective endocarditis in HIV positive, non-IVDAs 
The clinical profile including bacteriology of infective endocarditis in HIV is different 
from HIV uninfected patients. The clinical impact of the HIV epidemic on infective 
endocarditis in Africa has not been elucidated in the world literature. There is a paucity of 
literature addressing this reported, rare, clinical entity of HIV and IE in Africa.²² 
 
The relationship between HIV/AIDS and infective endocarditis and its implications in 
non-intravenous drug abusers has not been clearly and completely defined.¹, ²², ²⁵ 
Reported studies worldwide do not support the notion that in intravenous drug abuse HIV 
alone is an independent risk factor for infective endocarditis. This seems to suggest that 
concomitant intravenous recreational drug abuse, ², ²⁷ in Western countries, is 
confounding the apparent association with HIV.  
 
In Cape Town, in 2003, Koegelenberg et al.¹ observed that in non-intravenous drug abuse 
only one (2.9%) of the 34 patients with definite IE who were tested actually had positive 
serology for HIV; this supports the view that HIV is not an independent risk factor for 
developing IE.  However, in IVDAs, it has been suggested that HIV infection related to 
immunodeficiency may independently increase the risk of infective endocarditis among 
injecting drug users.², ²⁶, ²⁷ The degree of HIV induced immunosuppresion in IVDAs has 
shown to modify the IE clinical characteristics and the outcome.²⁷, ²⁸  The overall 
mortality for HIV-infected or non-HIV infected IVDA with IE is similar. However, among 
HIV-infected IVDA, mortality is significantly higher in those who are most severely 
immunosuppressed, with CD4+ cell counts below 200cells/µL or with AIDS criteria and left-
sided endocarditis.²⁷, ²⁹, ³¹ ⁻ ³⁷ Moreover, it has been reported that infective endorcarditis 
in IVDA and HIV infected patients is not exclusively associated with intravenous drug 
abuse behaviour, as left-sided and mixed endocarditis has been reported.²⁹ − ³⁴  
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The clinical patterns of IE in HIV positive patients with non-IVDAs are not well 
established and defined due to the reported low prevalence of IE in this sub-group in the  
literature.¹, ²⁵ There are very few studies that have looked at the clinical pattern and 
prognosis of infective endocarditis in non-IVDA HIV infected patients in Africa. ¹, ³⁸, ³⁹, 
⁴⁰, ⁴¹   
 
A series of case reports on non-IVDA and HIV infected patients have been published 
outside Africa, which support the notion that infective endocarditis, is rare in HIV 
infected patients in the absence of intravenous drug abuse.²⁵, ⁴² ⁻ ⁵⁵, ⁵⁹ 
 
In Africa, and particularly in Sub-Saharan Africa, where HIV is pandemic and where 
rheumatic valvular heart disease is the main risk factor for developing infective 
endocarditis, in this setting (and affecting similar demographic groups of patients), there 
is significant potential to observe a significant number of patients with infective 
endocarditis and with underlying rheumatic valvular disease who are coincidentally 
infected with HIV.  
 
1.2  OBJECTIVE 
The objectives of this study are:  
1.  To highlight the co-existing diagnosis of HIV and IE in non-intravenous drug 
abusers; in the same patient is not rare in Africa  
2.  To describe three cases diagnosed with HIV and infective endocarditis at an 
institution (Chris Hani Baragwanath Hospital) within a period of two months.  
3.  To perform literature search on HIV/AIDS and infective endocarditis in non -
intravenous drug abusers using the MEDLINE search engine covering the period 
January 1985 to December 2006.   
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CHAPTER TWO 
 
 
 
2.1  MATERIALS AND METHODS 
 
2.1.1  Study design  
This is a retrospective case report and literature review study of infective endocarditis in 
HIV infected patients who are non-intravenous drug abusers. 
 
 
2.1.2  Source of patients: Case reports   
Three adult patients diagnosed with infective endocarditis and concomitant HIV disease 
at the department of cardiology, Chris Hani Baragwanath Hospital, between 1 April and 
31 May 2006 were included in this study. All patients gave written consent to the HIV 
test. Ethical approval was obtained from the University of the Witwatersrand, Human 
Research Ethics Committee (Medical) - see the copy at Appendix 1. 
 
The clinical data were obtained from patient record files, hospital charts and video 
cassette tapes from the Department of Cardiology after being granted permission from the 
hospital administration.   The study was performed between April and May 2006. 
 
Inclusion criteria 
 
Patients described in this study fulfilled the following criteria: 
 
1.  IE: The diagnosis of IE was made according to the 1994 Dukes criteria.⁵⁶ 
 
2.  HIV infection: HIV infection was confirmed by two positive ELISA tests or a 
positive ELISA test plus a positive Western blot test.  
 
3.  Neither active nor previous IVDA. 
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2.1.3  Review of the Literature 
The systematic review of cases published in literature between January 1985 and 
December 2006 and delivered by MEDLINE SEARCH. The following key words were 
used: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, 
Rheumatic Heart Disease, Infective Endocarditis, and Intravenous Drug Abusers 
and Non-Intravenous Drug Abusers. The references quoted in this study were reviewed 
for their relevance. Cases were accepted if they fulfilled the inclusion criteria described 
above and if they were well described. Only papers in English, Spanish and French were 
considered. Where articles in Spanish and French were identified, only abstracts were 
used. 
 
2.1.4  Ethics 
Ethical approval was obtained from the Human Research Ethics Committee (Medical) of 
the University of the Witwatersrand, clearance certificate protocol number M060714. See 
the copy provided at Appendix 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9
CHAPTER THREE  
 
3.1  RESULTS - CASE REPORT  
Three adult patients admitted at Chris Hani Baragwanath Hospital between 1 April and 
31 May 2006 fulfilled the inclusion criteria and the diagnosis of infective endocarditis, 
according to modified Duke Criteria⁵⁶, ⁵⁷ as summarized below in Table 1, and were 
confirmed as having HIV infection. Their clinical profiles and the outcome of each 
individual case are described below in Table 1 below.   
 
3.1.1  Case 1  
3.1.1.1  Clinical presentation  
A 23 year old female patient was admitted to the medical ward on 30 May 2006, 
presenting with acute onset of shortness of breath on mild exertion, associated with a 
persistent fever, anorexia, fatigue, malaise and oligoarthalgias for the duration of four 
days. She denied the use of antibiotics prior to admission; she had never been diagnosed 
with rheumatic heart disease or thrombotic illness nor documented miscarriage 
previously. 
 
On admission, she was febrile, with a temperature of 39⁰ degree Celsius, and 
tachypnoiec, with a respiratory rate of 36 breaths per minute. She had a tachycardia of 
156 beats per minute, differential arterial pulse volume and weak right radial and dorsalis 
pedis pulse compared with the respective left side. Her blood pressure was 134/68 
mmHg. She had pedal oedema, raised jugular venous pressure, pallor and generalized 
short lymphoadenopathy, but with no significant features of HIV stigmata. Her glucose 
on haemoglucotest was 4.5mmol/l.  A urine dipstick test showed haematuria and 
proteinuria of less than 1g.  The heart was clinically enlarged with the apex beat 
displaced in the sixth intercostals space lateral to the mid-clavicular line.   
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Table 1: Definitive diagnosis of infective endocarditis fulfilling modified Duke Criteria for the three cases selected  
 
 
 
Duke Criteria       Case 1                                              Case 2                                           Case 3            
 
 
     Major Criteria   ***Vegetation on Mitral valve.           **Vegetation on Aortic valve.           *Vegetation on Aortic valve.  
                                                                                 
 
     Minor Criteria           Predisposing rheumatic                  Predisposing rheumatic                    Predisposing rheumatic heart 
                                       heart disease.                                  heart disease.                                    disease. 
                           
                                       Fever: 39.0 degree Celsius.            Fever: 38.5 degree Celsius               Fever: 38.9 degree Celsius  
                                           
                                       Vascular phenomena;                     Vascular phenomena;                      Vascular phenomena;                        
                                       arterial thrombus                             subconjuctival haemorrhage,          arterial thrombus   
                                                                                               Splenomegaly and clubbing 
                                                                                                     
                                       Elevated C-reactive protein and     Elevated C-reactive protein and      Elevated C-reactive protein and   
                                       erythrocyte sedimentation rate       erythrocyte sedimentation rate        erythrocyte sedimentation rate 
 
 
 **Vegetation confirmed on both Transthoracic and Transoesophageal Echocardiogram; **only on Transthoracic Echocardiogram, and; *Transoesophageal 
Echocardiogram
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Auscultation revealed a left-sided third heart sound - a feature of left-heart failure with a 
3/6 pansystolic murmur, most audible at the apex and radiating to the axilla, which 
signified mitral incompetence. A chest examination revealed bilateral basal crackles. The 
liver was palpable three centimeters below the right costal margin, tender and having a 
smooth surface and sharp margin. No spleen was felt on abdominal examination. She had 
a tender right shoulder, left elbow, right elbow and right knee without features of arthritis. 
Fundoscopy examination was normal. No hemorrhage or Roth’s spots were reported. 
 
3.1.1.2  Investigations 
 
3.1.1.2.1  Imaging tests 
 
3.1.1.2.1.1  Chest X-ray 
The Chest X-ray showed an increased cardiothoracic ratio of more than 60% and features 
of pulmonary oedema, without other parenchymal lung features suggestive of an infective 
process. 
 
3.1.1.2.1.2  Electrocardiography 
The electrocardiography revealed sinus tachycardia with a rate of 120 beats per minute, a 
PR- interval of 0.16 seconds, normal p-waves configuration and voltage. The QRS 
complex axis was normal at + 60⁰. See Figure 2 below. 
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Figure 2: ECG of a 23 year old patient (Case 1) on admission  
 
 
3.1.1.2.1.3  Transthoracic echocardiography 
Transthoracic echocardiography showed large mobile vegetation (2.2cm) on the anterior 
mitral valve leaflet flopping into the left atrium. The mitral valve was thickened, with 
calcification on both leaflets and with moderate to severe mitral regurgitation. The left 
ventricle had a normal end-diastolic diameter of 4.9cm and a normal end-systolic 
diameter of 2.8cm, resulting in a fractional shortening of 42% and ejection fraction of 
73%.  She had mild aortic regurgitation and moderate tricuspid regurgitation with a right 
ventricular systolic pressure of 30mmHg. See Figure 3 below.  
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Figure 3: Transthoracic echocardiography of a 23 year old patient (Case 1) showing a     
                 large vegetation on the mitral valve both on anterior and posterior leaflet 
 
 
 
3.1.1.2.1.4  Transoesophageal echocardiography 
Transeosophageal echocardiography was performed to exclude vegetation on the aortic 
valve. This revealed the large vegetation on the anterior and posterior mitral leaflets. The 
aortic valve was normal, except for mild calcification. No vegetation was seen on the 
aortic valve. See Figure 4 and Figure 5 below. 
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Figure 4: Transoesophageal echocardiography of a 23 year old patient (Case 1) showing  
                 large vegetations on the tips of both anterior and posterior mitral valve leaflets  
 
 
 
Figure 5:  Transoesophageal echocardiography of a 23 year old (Case 1) revealing the     
            aortic valve without vegetation, but confirming the vegetation on the mitral valve 
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3.1.1.2.2.  Laboratory blood results and culture 
On admission, her full blood count revealed: leucocytosis with a white cell count of 14.7 
x 10⁹/l; anaemia of a chronic disorder with haemoglobin of 6.5g/dL; and 
thrombocytopenia with a platelets count of 48 x 10⁹/l. The inflammatory markers were 
raised (Table 2). The prothrombin time was prolonged (Table 2). Her HIV ELISA tests 
were positive twice with CD4+ count of 203cells/μl and viral load less than 25 RNA 
copies/µl. The antinuclear antibody test was negative. The sets of all blood cultures taken 
before antibiotics were initiated on admission were negative. Table 2 below demonstrates 
detailed blood results on admission. 
 
3.1.1.3  Diagnosis  
Based on the findings above, the definitive diagnosis of negative blood culture infective 
endocarditis with vegetation on the mitral valve was established (Table1). Disseminated 
intravascular coagulopathy (DIC) was also diagnosed as secondary to sepsis in view of 
the fact that her prothrombin time was prolonged and she was thrombocytopenic.  
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Table 2: Laboratory results on admission of a 23 old patient (Case 1). 
 
 
Wcc; White cell count, Hb; Haemoglobin, Hct; Haematocrit, MCV; Mean Corpuscular Volume, Neutr; Neutrophils, Mono; Monocytes, Baso; Basophils, Eos; 
Eosinophils, Lymp; Lymphocytes,  CRP; C-reactive protein, ESR; Erythrocyte sedimentation Rate, GGT; Gamma glutamyltransferase, ALT; Alanine 
aminotransferase, AST; Aspartate aminotransferase, LDH; Lactate dehydrogenase, PTTp; Partial prothrombin time patient, PTTc; Partial prothrombin time 
control, INR; International normalization ratio, S-Iron; Serum Iron level. 
 
FBC→ 
 
 
Wcc 14.7  
x 10⁹/l  
  
 
Hb.  
6.3 g/dl 
 
 
Hct 
0.180 
 
 
MCV  
84.9 fl  
 
 
Platelets 
48 x 10⁹/l 
 
Neutr.   
72.5 % 
 
Mono. 
11.2 % 
 
Lymph 
16.2% 
 
Eos.   
0.1 % 
 
Baso. 
0.1 % 
       
Creatinine  
 
85 µmol/l 
          Blood Culture 
All six sets taken were 
negative 
Urea and 
Electrolytes → 
Potassium 
 
3.2 mmol/l 
Sodium 
 
134 mmol/l 
Chloride 
 
92 mmol/l 
Carbon 
dioxide 20 
mmol/l 
Urea  
 
6 mmol/l  
 
Total liver function 
tests → 
Total 
bilirubin 23 
µmol/l  
Direct 
bilirubin  
13 µmol/l  
Total 
protein  
 68 g/l   
Albumin  
 
22 g/l 
Alkaline 
phosphate 
71 U/l  
GGT 
 
21 U/l 
ALT 
 
16 U/l 
AST 
 
54 U/l 
 
Inflammatory 
markers→ 
 
CRP 
 
134 mg/l 
 
ESR 
 
50 
mm1sthour 
 
Iron Studies → 
 
S- Iron  
 
28 µmol/l 
 
Transferrin 
  
3 g/l 
 
%Saturation 
29% 
 
Ferritin 
 
108 ng/ml 
 
HIV Positive ELISA 
test → 
 
 
 
CD4+ 
 
203 cells/µl
 
Viral load 
 
25 copies/µl 
 
Coagulation  
Test → 
 
PTTp 
 
 48.3 
 
PTTc   
 
24.2 
 
INR  
 
1.81 
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3.1.1.4  Treatment and clinical outcome  
After admission to the medical ward, establishment of the diagnosis and three blood 
culture sets being taken, the patient was started on intravenous antibiotics:  penicillin G 4 
million units 4-hourly, cloxacillin 2g 6-hourly, gentamicin 80 mg 8-hourly. She was 
transfused one unit of packed red cells - her haemoglobin was 6.3 g/dl. Within 24 hours 
she deteriorated clinically:  her blood pressure dropped, she became hypotensive and her 
heart failure worsened. She was transferred to the Coronary Care Unit (CCU) where her 
haemodynamics, blood pressure, pulse rate, oxygen saturation, fluid intake and output 
were closely monitored. She was started on: inotrope dobutamine infusion to augment the 
cardiac contractility, so as to raise the blood pressure and improve cardiac output; and 
diuretics furosemide (lasix) intravenously, for pre-load reduction as an anti-failure 
treatment, with a potassium supplement to replenish the loss of potassium caused by the 
diuretic (lasix) administration.  
 
The patient showed significant clinical improvement within 72 hours in CCU. Her 
thrombocytopenia improved and the prothrombin time normalized in response to 
intravenous antibiotics therapy. 
 
On the sixth day in the coronary care unit, she had a single episode generalized seizure - 
on examination she was found to be afebrile and normoglycaemic. On clinical 
examination, she showed no features of menigism. The brain CT scan was done to 
exclude space occupying lesions and revealed normal findings. A lumbar puncture 
performed was also normal. On the tenth day she developed right lower lobe pneumonia 
and was subsequently started on tazocin (piperacillin / tazobactam) 4.5g 6-hourly, 
intravenously. She developed what was suspected to be septic shock with multiple organ 
dysfunctions.  She was subsequently intubated and ventilated on the mechanical 
ventilator. The transthoracic echocardiography then revealed increased pulmonary arterial 
pressure of 76mmHg, a slightly dilated right-side and tricuspid regurgitation, with good 
preserved left ventricular function at an ejection fraction of 70%. A pulmonary embolus 
was suspected and a full anticoagulation heparin infusion was initiated. Unfortunately, 
 18
the patient died before the diagnosis was confirmed on the eleventh day. No autopsy 
study was performed. 
 
3.1.2  Case 2 
3.1.2.1  Clinical presentation 
A 46 year male patient presented at the cardiac clinic on 30 April 2006, with: a one-week 
history of night sweats, fever,  productive cough with mild to moderate haemoptysis, 
dyspnoea grade four, orthopnea, paroxysmal nocturnal dyspnoea and bilateral painless 
leg swelling. Previously, he had been diagnosed with rheumatic valvular heart disease, 
mitral and aortic regurgitation and been admitted at the same institution on 23 March 
2006 with biventricular heart failure. His left ventricular function on that particular 
admission was preserved, with an ejection fraction of 60%. 
 
On admission he was febrile, with a temperature of 38.5 degree Celsius, and tachypnoiec, 
with a respiratory rate of 40 breaths per minute. He had a tachycardia with a pulse rate of 
116 beats per minute, a collapsing pulse and both the Corrigan`s sign and Durrozeiz`s 
sign were positive. His blood pressure was normal, at 102/51 mmHg, with a wide pulse 
pressure. He had raised jugular venous pressure, pedal oedema, digital clubbing, clinical 
pallor, wasting and sub-conjuctival hemorrhage with generalized short 
lymphoadenopathy. The cardiac examination showed an enlarged heart - the apex beat 
displaced in the 6th intercostals space lateral to the mid-clavicular line. He had apical 
systolic thrill, left parasternal heave and a palpable P₂ component of the second heart 
sound. Auscultation revealed a loud P₂, left-sided third heart sound, the mitral 
incompetence murmur 3/6 apical pansystolic murmur radiating to the axilla and the aortic 
incompetence murmur, with early diastolic murmur 3/6 louder at the left sternal edge. 
Chest examination demonstrated bilateral scattered crackles with wheezing and he had no 
bronchial breathing sound pointing to severe pulmonary oedema. The liver was palpable 
6cm below the right costal margin, tender and smooth. He had a splenomegaly of 3cm 
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below the left intercostals space mid-clavicular line with ascites. Urine dipsticks showed 
haematuria and proteinuria of less than 1g.  
3.1.2.2  Investigations 
3.1.2.2.1  Imaging tests 
3.1.2.2.1.1  Chest X-ray  
Chest X-ray showed an increased cardiothoracic ratio of more than 80%, in keeping with 
an enlarged left ventricle due to increased left ventricular volume from severe aortic 
regurgitation. The parenchymal lung fields demonstrated diffuse severe pulmonary 
oedema. 
 
3.1.2.2.1.2  Electrocardiography 
Electrocardiography showed sinus normal rhythm, a rate of 96 beats per minute, left axis 
deviation and left ventricular hypertrophy with left ventricular strain secondary to volume 
overload from severe aortic regurgitation. See Figure 6 below. 
 
 
Figure 6: ECG of a 46 year old patient (Case 2) 
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3.1.2.2.1.3  Transthoracic echocardiography 
 
Transthoracic echocardiography showed a rheumatic mitral valve, both anterior and 
posterior leaflets moderately thickened with moderate to severe mitral regurgitation. The 
left ventricle was dilated with an end-diastolic diameter of 7.2cm and an end-systolic 
diameter of 5.4cm, producing a fraction shortening of 25% and an ejection fraction of 
45%, thereby demonstrating left ventricular systolic dysfunction. The aortic valve cusps 
(non-coronary, right and left coronary) were all thickened and calcified with vegetation 
less than 10mm thick and showed severe aortic regurgitation. The patient had tricuspid 
regurgitation with an elevated pulmonary arterial pressure of 40mmHg. See Figure 7 
below. 
 
 
 
Figure 7: Transthoracic echocardiography of a 46 year old patient (Case 2) showing 
vegetation on aortic valve with calcified cusps 
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3.1.2.2.2  Laboratory blood results and culture 
On admission the patient’s full blood count revealed: a normal white cell count of 8.7 x 
10⁹/l, a normal platelets count of 236 x 10⁹/l, anaemia of chronic disorder with 
haemoglobin 7.8g/dL and low mean corpuscular volume of 78fl with iron deficiency 
picture, low serum iron level, low percentage iron saturation with normal transferring and 
ferritin levels. The inflammatory markers were slightly raised. He had two ELISA HIV 
tests, which were both positive, with a CD4+ count of 556 cells/μ/l and a viral load of 
68,880 RNA copies/µL.  
 
He had mild renal dysfunction, with a slightly elevated urea of 10.7mmol/l and creatinine 
128µmol/l. He had mild cholestatic hepatitis, with the gamma glutamyltransferase 
elevated fourfold and slight elevated alkaline phosphatase, with normal synthetic liver 
function. The sets of all blood cultures taken before antibiotics were given were negative. 
Table 3 below shows detailed results of all tests on admission. 
 
3.1.2.3  Diagnosis  
Based on the findings above, the definitive diagnosis of negative blood culture infective 
endocarditis with vegetation on aortic valve was established (Table 1). 
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Table 3: Laboratory results on admission of a 46 old patient (Case 2) 
 
 
Wcc -  White cell count; Hb - Haemoglobin; Hct - Haematocrit; MCV - Mean Corpuscular Volume; CRP - C-reactive protein; ESR - Erythrocyte sedimentation 
Rate; Compliment C3 - Compliment C4; GGT - Gamma glutamyltransferase; ALT - Alanine aminotransferase; AST - Aspartate aminotransferase; LDH - 
Lactate dehydrogenase; PTTp - Partial prothrombin time patient; PTTc - Partial prothrombin time control;  INR - International normalization ratio;  S-Fe - Serum 
Iron level; Trans - Transferrin; % Sat - Percentage saturation; Ferri - Ferritin; CD4+( *433) repeated after six week of antibiotics. 
 
FBC→ 
 
 
Wcc  
 8.7 x 10⁹/l 
 
Hb.  
 
7.8 g/dl 
 
Hct 
 
0.232 
 
MCV  
78 fl              
 
Platelets 
236x10⁹/l 
 
Neutr.   
 
60 % 
 
Mono. 
 
6 % 
 
Lymp 
 
32.7 %
 
Eos.   
 
0.1 % 
 
Baso. 
 
0.2 % 
       
Creatinine  
 
128 µmol/l 
          Blood Culture 
All six sets were negative Urea and 
Electrolytes → 
Potassium 
 
4.3 mmol/l
Sodium 
 
146 mmol/l 
Chloride 
 
104 mmol/l 
Carbon 
dioxide. 
19mmol/l 
Urea  
 
10.7 mmol/l 
 
Total liver function 
tests → 
Total 
bilirubin 
18 µmol/l  
Direct 
bilirubin  
11 µmol/l  
Total 
protein  
89  g/l    
Albumin  
 
31 g/l 
Alkaline 
phosphate 
  139 U/l 
GGT 
 
163 U/l 
ALT 
 
23 U/l 
AST 
 
35 U/l 
LDH 
 
35 U/l 
 
Inflammatory 
markers→ 
 
CRP 
 
36 mg/l 
 
ESR 
 
45 
mm1sthour 
 
Iron Studies → 
 
S- Iron  
 
4.1 µmol/l  
 
Transferrin 
 
3.3  g/l 
 
%Satura
tion 
5% 
 
Ferritin 
 
51 ng/ml 
 
HIV Positive ELISA 
test → 
 
 
 
CD4+ 
 
556 cell/µl 
(*433) 
 
Viral load 
 
68,880 
copies/µl  
 
Coagulation  
Test → 
 
PTTp  
 
 
26.5 
 
PTTc   
 
 
27.8 
 
INR  
 
 
1.56 
 
C3   
 
 
1.090 
 
C4  
 
 
0.139 
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3.1.2.4  Treatment and clinical outcome  
After establishment of a definitive diagnosis, the patient was started on intravenous 
antibiotics in the medical ward: penicillin G 4 million units’ 4-hourly, cloxacillin 2g 6-
hourly, gentamicin 80mg 8-hourly.  Other therapies given were: Adalat (nefedepine long 
acting) XL 30mg (daily) orally for aortic regurgitation; diuretics for pre-load reduction to 
relieve the congestion and raise the cardiac output;  furosemide (lasix) 80mg mane and 
80mg nocte intravenously and aldactone 50mg (daily) orally. Perindropril (coversyl) 2mg 
(daily) orally was given as a vasodilator to reduce systemic peripheral resistance and 
support cardiac output. He was given prophylactic anticoagulation unfractionated heparin 
5000u 12-hourly subcutaneously, to prevent systemic venous coagulation, and ferrous 
sulphate 200mg 8-hourly supplementation due to a low level of serum iron.  
 
He was transferred to Coronary Care Unit (CCU) on the eighth day, due to refractory 
heart failure, persistent fever, haemodynamic instability and worsened renal dysfunction. 
In CCU, the medical therapy was optimized. He was started on: inotrope dobutamine 
infusion, to improve the cardiac contractility and raise the blood pressure; and a 
vasodilator nitrocine infusion, to reduce systemic peripheral vascular resistance and 
improve the cardiac output. Strict fluid management was instituted, balancing input and 
output, gentamicin level was monitored and he was transfused with two units of packed 
red cells as his haemoglobin dropped from 7.8g/dl to 5.9g/dl.   
 
The cardiothoracic surgeons were consulted and accepted the patient for emergency 
aortic and mitral valve replacement with tricuspid annuloplasty at Johannesburg Hospital. 
Unfortunately, surgery was not performed due to unavailability of a bed in the Intensive 
Care Unit at Johannesburg Hospital. The surgeons were constantly informed of the 
progress of the patient, who improved significantly on medical therapy and it was 
decided to take him to surgery after completion of his full intravenous antibiotics therapy 
for infective endocarditis. 
 
He completed four weeks of intravenous antibiotics, with significant clinical 
improvement in CCU. His left ventricular systolic function improved from a 45% 
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ejection fraction, on admission, to 58%. The aortic vegetation resolved and disappeared 
on transthoracic echocardiography. The transoesophageal echocardiography was not 
performed to confirm the findings, due to the patient declining consent. He was 
transferred from CCU to a medical ward, where he completed eight weeks of intravenous 
antibiotics and was discharged in a stable condition and awaiting elective surgical 
therapy.        
 
The patient was re-admitted on 23 June 2006 in a decompensated state and worsened 
biventricular heart failure. He had a raised jugular venous pressure, mild pedal oedema, 
ascites, a tender congested liver and gallop rhythm. Generally, the patient was afebrile 
with a temperature of 37 degree Celsius, a blood pressure of 161/74mmHg and a pulse 
rate of 108 beats per minute. Chest examination revealed features of left lower lobe 
pneumonia, complicated to small para-pneumonic exudative pleural effusion, which were 
confirmed by chest ray. 
 
The transthoracic echocardiography was unchanged from the previous admission. It 
demonstrated the same severity of aortic and mitral incompetence as on the first 
admission. However, aortic vegetation and root abscess was suspected, but could not be 
confirmed on transoesophageal echocardiography as, once again, the patient declined 
consent. Magnetic Resonance Imaging (MRI) was performed, which did not confirm the 
aortic root abscess.       
 
On this re-admission he had: mild anaemia with haemoglobin of 10.4g/dl, a normal white 
cell count of 9.68 x 10⁹/l, and a normal platelets count of 208 x 10⁹/l. The inflammatory 
markers were significantly elevated. The renal function was worse when compared to the 
first admission: urea was 22.6mmol/l and creatinine was 139µmol/l. His CD 4+ count 
dropped from 556cells/μl to 433cells/μl. The blood culture; of a single set of three sets 
taken, cultured coagulase negative Staphylococci bacteria sensitive to cloxacillin and 
vancomycin within 24 hours. The subsequent cultures failed to yield the same organism. 
Although the blood culture evidence was not strong enough to support the diagnosis of 
infective endocarditis, he was treated with caution due to atypical presentation of 
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endocarditis in an HIV patient. Table 4 below shows the results of all tests done on re-
admission. 
 
He was started on intravenous antibiotics: ceftriaxone 2g daily, cloxacillin 2g 6-hourly 
and vancomycin 750mg 12-hourly, with close monitoring of renal function and 
vancomycin serum level. He was also started on an intravenous inotrope, dobutamine and 
a vasodilator (glyceryl trinitrate) infusion. The cardiothoracic surgeons were re-consulted 
and in principal accepted him for surgical therapy. Unfortunately, he died before he was 
transferred to Johannesburg Hospital for surgery on 17 July 2006. 
 
3.1.3  Case 3    
3.1.3.1  Clinical presentation 
A 37 year old male patient was admitted on 22 May 2006 and presented at the medical 
admission ward with: a three-week history of fever, night sweats, a  productive cough 
with mild haemoptysis, bilateral painless lower limb swelling, dyspnoea grade four, 
orthopnea, and paroxysmal nocturnal dyspnoea. He has no previous documented history 
of rheumatic valvular heart disease.  
 
On admission, he was febrile, with a temperature of 38.9 degree Celsius, and 
tachypnoiec, with a respiratory rate of 30 breaths per minute. He was tachycardiac, had a 
heart rate of 114 beats per minute and a differential pulse volume that was absent on the 
right dorsalis pedis associated with acrocynosis on the first, second and third toe. He was 
hypotensive, with blood pressure of 92/65 mmHg. His internal jugular venous pressure 
was raised. He had clinical pallor, generalized short lymphoadenopathy, temporal wasting 
oral thrush and was jaundiced.  
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Table 4: Laboratory results of a 46 year old patient (Case 2) on re-admission  
 
 
 
Wcc - White cell count; Hb - Haemoglobin; Hct - Haematocrit; MCV-  Mean Corpuscular Volume; CRP - C-reactive protein; ESR - Erythrocyte sedimentation 
Rate; GGT - Gamma glutamyltransferase; ALT - Alanine aminotransferase; AST - Aspartate aminotransferase; LDH - Lactate dehydrogenase; PTTp - Partial 
prothrombin time patient; PTTc - Partial prothrombin time control; INR - International normalization ratio; S-Fe - Serum Iron level; Trans - Transferrin ; % Sat - 
Percentage saturation; Ferri - Ferritin. 
 
FBC→ 
 
 
Wcc 
9.68 x 
10⁹/l  
  
 
Hb.  
10.4 g/dl 
 
 
Hct 
0.322 
 
MCV  
82.5  fl  
 
 
Platelets 
208 x 
10⁹/l 
 
Neutr.   
60% 
 
Mono. 
7% 
 
Lymp 
29% 
 
Eos.  
6% 
 
Baso. 
3% 
       
Creatinine  
  
139 µmol/l 
          Blood Culture 
Single set Coagulase 
negative staphylococci 
Urea and 
Electrolytes → 
Potassium 
 
5.4 
mmol/l 
Sodium 
 
136 mmol/l 
Chloride 
 
101 mmol/l 
Carbon 
dioxide 19 
mmol/l 
Urea. 
  
22.6 mmol/l  
 
Total liver function 
tests → 
Total 
bilirubin 
11 µmol/l  
Direct 
bilirubin  
6 µ mol/l  
Total 
protein  
99 g/l   
Albumin   
 
39 g/l 
Alkaline 
phosphate  
215 U/l  
GGT 
 
187 U/l 
ALT 
 
50 U/l 
AST 
 
46 U/l 
 
Inflammatory 
markers→ 
 
CRP 
 
105 mg/l 
 
ESR  
 
220 mm 
in1st hour 
 
HIV Positive ELISA 
test → 
 
 
CD4+ 
 
433 cells/µl 
 
 
Coagulation  
Test → 
 
 
 
 
PTTp  
 
27.3 
 
PTTc  
 
28.7 
 
INR 
 
1.28 
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The heart examination demonstrated an enlarged heart; the apex beat was displaced in the 
6th intercostals space lateral to the mid-clavicular line. He had left parasternal heave, 
palpable P2 - a component of second heart sound. Auscultation revealed loud P2, left-
sided third heart sound -  a feature of left ventricular failure -  3/6 pansystolic murmur 
maximally audible at the apex and radiating to the axilla - in keeping with mitral 
regurgitation and apical mid-diastolic murmur 2/4 pointing to mitral stenosis, describing 
features of mixed mitral valve disease. Moreover, the auscultatory findings demonstrated 
aortic regurgitation murmur, an early diastolic murmur 2/4 louder at the left sternal edge 
on expiration and in a forward leaning position. The chest examination showed bilateral 
scattered crackles, demonstrating pulmonary oedema - a feature of left ventricular failure. 
The abdomen examination demonstrated an enlarged, tender liver with smooth and sharp 
edges. The urine dipsticks indicated haematuria and proteinuria of 1g/dl. 
 
3.1.3.2  Investigations 
3.1.3.2.1  Imaging tests 
3.1.3.2.1.1  Chest X-ray 
The chest X-ray demonstrated a cardiothoracic ratio of more than 80%, supporting 
clinical findings of enlarged left ventricle, enlarged left atrium, prominent pulmonary 
vessels and features of pulmonary oedema with small bilateral pleural effusion.   
      
3.3.2.1.1.2  Electrocardiography 
Electrocardiography showed tachycardia, with a rate of 115 beats per minute and 
occasional premature atrial ectopics, and left ventricular enlargement on voltage criteria. 
The QRS complex axis was +90⁰, as seen in Figure 8 below.   
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Figure 8: ECG of a 37 year old patient (Case 3) on admission 
 
 
3.1.3.2.1.1.3  Transthoracic echocardiography  
 
Transthoracic echocardiography demonstrated a rheumatic mitral valve, with thickened, 
retracted and calcified posterior leaflet. It revealed severe mitral stenosis, as the mitral 
valve area on planimetry measured 0.6cm² and had a doppler pressure half-time of 
0.8cm². The maximum pressure gradient was 42mmHg; the mean pressure gradient was 
18mmHg with moderate mitral regurgitation.  In terms of the aortic valve: all cusps were 
thickened, retracted and calcified, with suspected vegetation on the tip of the cusps and 
with severe aortic incompetence. The left ventricle was dilated, with an end-diastolic 
diameter of 6.1cm and end-systolic diameter of 4.9 cm, giving a fraction shortening of 
22% and an impaired left ventricle function ejection fraction of 42%. The patient had 
tricuspid regurgitation, with right ventricular systolic pressure of 88mmHg and small 
pericardial effusion.   
 
3.1.3.2.1.1.4      Transoesophageal echocardiography 
Transoesophageal echocardiography confirmed the suspected vegetation on the 
transthoracic echocardiography - the vegetation of 10 mm in size, seen on the tips of the 
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aortic cusps - and revealed a large left atrial appendage mural thrombus (Figure 9 and 
Figure 10). 
 
Figure 9: Transoesophageal echocardiography showing the vegetation on aortic valve in 
a 37 year old patient (Case 3) 
 
Figure 10: Transoesophageal echocardiography showing mural thrombus in left atrial 
appendage in a 37 year old patient (Case 3) 
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3.1.3.2.2. Laboratory blood results and culture 
 
On admission, the patient’s full blood count demonstrated leucocytosis and a white cell 
count of 13.4 x 10⁹/l with relative neutrophilia on the background of lymphopenia.  He 
had aneamia of a chronic disorder, with haemoglobin 12g/dl and a normal platelets count. 
The inflammatory markers were significantly elevated. The ELISA HIV tests were 
positive twice, his CD4+ count was 67cells/μl and viral load was at 65,000copies/µl. A 
blood culture, a single set of the three sets taken on admission before starting antibiotics, 
yielded coagulase negative Staphylococci with suspicion of contamination. He had renal 
dysfunction, with elevated urea and creatinine associated with mild hyperkalaemia, and 
liver dysfunction suggestive of severe sepsis from endocarditis with multiple organ 
dysfunctions. Table 5 below summarizes the detailed blood results on admission of this 
patient. 
 
3.1.2.3  Diagnosis  
Based on the findings above, the definitive diagnosis of negative blood culture infective 
endocarditis with vegetation on the aortic valve was established (Table1).  This diagnosis 
was complicated due to septic shock and multiple organ dysfunctions. 
 
3.1.3.3  Treatment and clinical outcome  
The patient was transferred to the Coronary Care Unit within 24 hours and started on 
intravenous antibiotics after the blood cultures were taken. He was given: intravenous 
ceftriaxone 2g daily; gentamicin 80mg 8-hourly; cloxacillin 2g 6-hourly; with supportive 
therapy including dobutamine and adrenaline. He received additional therapy with a 
vasodilator infusion, diuretic infusion, oral fluconazole and enoxaparin (Clexane) 
subcutaneously.  His renal and hepatic dysfunction improved significantly on antibiotics 
during the first week of therapy. He was transfused two units of packed red cells blood, 
as his haemoglobin dropped from 12g/dl to 6.8g/dl. 
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In the second week, the patient developed pneumonia. Tazocin (piperacillin / tazobactam) 
4.5g 6-hourly intravenously was initiated immediately. Unfortunately, the patient died on 
the 12 June 2006.    
 
The clinical profile and outcome of the three cases described in Chapter 2 are 
summarized below in Table 6.  
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Table 5: Laboratory results on admission of Case 3 
 
 
Wcc - White cell count; Hb - Haemoglobin; Hct - Haematocrit; MCV - Mean Corpuscular Volume; CRP - C-reactive protein; ESR - Erythrocyte sedimentation 
Rate ; GGT - Gamma glutamyltransferase ; ALT - Alanine aminotransferase ; AST - Aspartate aminotransferase ; LDH - Lactate dehydrogenase; PTTp - Partial 
prothrombin time patient,  Hepatitis B and C negative; PTTc - Partial prothrombin time control; INR - International normalization ratio; S-Fe - Serum Iron level.
 
FBC→ 
 
 
Wcc  13.4 
x 10⁹/l 
 
Hb.  
12 g/dl 
 
 
Hct 
0.38 
 
MCV  
 80.2 fl  
 
 
Platelets 
241 x 10⁹/ 
 
Neutr.   
92.7% 
 
Mono. 
4.3% 
 
 
 
 
Lymp 
2.9% 
 
 
 
       
Creatinine  
 
130 µmol/l 
          Blood Culture 
Single Set of three sets  
Cultured Coagulase  
negative Staphylococci 
Urea and 
Electrolytes → 
Potassium 
 
6 mmol/l 
Sodium 
 
130 mmol/l 
Chloride 
 
96 
mmol/l 
Carbon 
dioxide. 
20 
mmol/l 
Urea  
 
20.3 mmol/  
 
Total liver function 
tests → 
Total 
bilirubin 
100 µmol/l 
Direct 
bilirubin  
41 µmol/l  
Total 
protein  
59 g/l   
Albumin  
22 g/l 
Alkaline 
phosphate  
123 U/l  
GGT 
44 U/l 
ALT 
542 U/l 
AST 
125 U/l 
 
Inflammatory 
markers→ 
 
CRP 
 
213 mg/l 
 
ESR 
110 mm1st 
hour 
 
Iron Studies → 
 
S-Iron  
 
4.1 µmol/l 
 
Transferrin 
  
 1.4 g/l 
 
% 
Saturation  
 
12% 
 
Ferritin 
 
301 ng/ml 
 
HIV Positive ELISA 
test → 
 
 
 
CD4+ 
67 cells/µl 
 
Viral load 
65,000 
copies/µl 
Coagulation  
Test → 
 
PTT  27.5 
 
PTTc 29.6 
 
INR 1.0 
Hepatitis studies B 
Negative  
 C  
Negative  
A 
Negative  
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Table 6: Summary of clinical profile and outcome for the three cases described in Chapter 2 
 
 
                                                                   Case 1                                        Case 2                                     Case 3 
 
 
Age (years)                                                    23                                                46                                            37   
 
Gender                                                                 Female                                         Male                                       Male 
 
HIV CD4+ Count                                          203 cells/µL (423)                      556 cells/µL (433)                   67 cells/µL 
                                               
 
Viral load                                                       < 25 copies/µL                            68,880 copies/µL                    65,000 copies/μL                                        
 
Aetiology - Blood Culture                             Negative                                    Negative                                  Negative 
 
Underlying rheumatic valvulopathy            None                                         Aortic and Mitral valve          Mitral and Aortic Valve                
 
Echocardiographic Vegetation site              Mitral Valve                              Aortic valve                            Aortic Valve 
 
Co-morbid and Complications                     DIC, Suspected Pulmonary       Renal dysfunction                   Renal dysfunction  
                                                                         Embolus                                                                                    LAA thrombus 
                                                                          
Therapy                                                           Intravenous antibiotics              Intravenous antibiotics          Intravenous antibiotics 
 
Outcome                                                          Death                                         Death                                     Death 
 
 
DIC - Disseminated Intravascular Coagulopathy; LAA - left Atrial Appendage.  
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3.2  RESULT OF LITERATURE REVIEW  
The researcher performed a Medline search of literatures using the following key words: 
human immunodeficiency virus, acquired immunodeficiency syndrome, rheumatic 
heart disease, infective endocarditis, intravenous drug abusers and non-intravenous 
drug abusers. The search time-frame was January 1985 to December 2006. Most 
articles used were identified in English; where other language articles (French and 
Spanish) were identified, only abstracts were used.  
 
The researcher found forty-four (44) cases of infective endocarditis with HIV not related 
to intravenous drug abuse in literature published between January 1985 and December 
2006. Among these cases, 24 reported the gender of the patient (22 male and 2 female). 
In 21 cases, the age was reported, which ranged from 29 - 64 years. In 23 cases, no age 
was reported.  
 
The mean CD4⁺ count was 161cells/µl, ranging from 4 - 922 cells/µl among 36 known 
CD4⁺ cases; in 9 cases the CD4⁺ count was not reported. The causative microorganisms 
were reported in 36 of 44 cases (80%): 32 had bacterial endocarditis; 4 were fungal 
endocarditis. Among bacterial endocarditis, the common organism isolated was probably 
Staphylococcus aureau. However, there was one definitive case reported and one was 
Methecillin Resistance Staphylococcus aureus (MRSA). Nel et al., ³⁸ in their prospective 
observational study, described 13 cases - among them the common isolated organism was 
Staphylococcus aureau. Other isolates were:  
• Enterococcus   fecalis ; 4  
• Salmonella enteritidis ; 4 
• Streptococci viridians ; 2  
• Streptococcus pneumoniae ; 2  
• Listeria monocytogenes ; 1  
• Salmonella typhimurium ; 1  
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• Streptococcus agalactiae ; 1  
• Coagulase negative - staphylococci ; 1  
• Coxiella burnettii ; 1  
• Bartonella quintana ; 1  
• Fungal endocarditis - Candida albicans ; 1     
• Candida   zeylanoides ; 1  
• Aspergillums fumigates ; 2 
• Pseudallescheria boydii ; 1 
 
The majority of cases (89% - 40 cases) were native valve endocarditis; prosthetic valve 
endocarditis totalled only 5%. Among the case, the following additional information was 
provided:  
• 26% : aortic valve endocarditis 
• 24% : mitral valve endocarditis 
• 10% : mixed mitral and aortic valve endocarditis  
• 2% (one case) : tricuspid bioprothesis valve endocarditis  
 
In 38% of cases the site of endocarditis was not reported.  
 
The reported pre-existing valvulopathy was in 16% of cases (7 cases: mitral valve – 2; 
aortic valve – 2; mixed aortic and mitral valve – 1; metallic prosthesis valve1 and 
bioprothesis valve - 1). There was no underlying valvulopathy in 29% of cases (13 cases); 
in 55% of cases (25 cases) the underlying valvulopathy was not reported.  
 
In terms of management among 46 cases reported in literature:  
• 15 cases (33%) underwent medical therapy 
• 11 cases had surgery (25%) 
• in 19 patients (42%) the mode of treatment was not reported and no data were 
available.  
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Among those who underwent medical therapy, 10 cases survived and 5 cases died. 
Among those who had surgery 7 cases survived and 4 cases died.  In 13 cases, the 
outcome data were not available.   
 
The findings showed that there are few reported studies of infective endocarditis not 
related to intravenous drug abuse in HIV infected patients in the literature, due to a 
relatively low prevalence of infective endocarditis. Most of these published studies are 
limited to a series of case reports, most of them originating outside Africa.²⁵, ⁴² ⁻ ⁵⁵, ⁵⁹   
 
There was no case report from Africa published in the literature and all the cases 
published were from prospective observational cohort-studies¹, ³⁸ - ⁴¹  
 
The detailed results of the literature search of cases with IE infected with HIV, non-
IVDAs are summarized below in Table 7. The variables described in the table may be 
inadequate, but briefly demonstrate the clinical profiles of these cases. 
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Table 7: IE in non-IVDA HIV infected patients described in the literature 
  
    
      Case   Ref.   Date   Age     Gender  HIV Stage     Aetiological                Type        Pre-existing     Valve                Echo-         Surgery        Outcome   
                                                           CD4              Agent                         of Valve   Valvulopathy   involved          Vegetation 
1        42       1990    No data     M        No data      Streptococci viridians            Native        No data          Mitral                   No data         No data            No data                              
  
2        43       1993    No data    M         No data     Enterococcus   fecalis             No              Mitral             No data               No data         No data            No data  
                                                                                                         
3        44       1991    54             M         25              Streptococcus  pneumoniae   Native        Aortic             Aortic                 Yes               No                     Survival 
   
4        45       1994   35              M         6                Streptococcus pneumoniae    Native        No                  Aortic                 Yes                No                    Survival 
                                                                                                       
5        46       1988   55              M         No data     Listeria  monocytogenes        Native        No                  Aortic & Mitral  Yes               Yes                   Survival  
 
6        47      1989   51              F          No data     Salmonella  typhimurium       Native        No                  Aortic & Mitral  Yes               No                    Survival 
 
7        48      1983   24              M         15              Salmonella enteritidi             Native        No data          No data               No data         No data           No data                                
 
8        49      1996   59              M         No data     Salmonella enteritidi             Prosthetic   Prosthesis     Mitral                  No                No                    Death  
                                                                                                      
9        49      1996   64              M         242           Salmonella enteritidis            Native         No                 Mitral                   No                Yes                  Survival    
                                                                                                     
10      50      1993   50              M        200           Bartonella quintana                Native         No                 Aortic & Mitral  Yes                No                   Survival 
                                                                                                     
11      51      1993   40               M       922          Candida albicans                     Prosthetic    Bio               Tricuspid             Yes               Yes                  Survival 
                                                                                                   
12      52      1996   44               M        < 50        Candida   zeylanoides             Native          No                Mitral                   Yes               No                   Death  
 
13      53     1990    31               M        12           Aspergillums fumigates           Native        No                  Mitral                   Yes               No                    Death  
 
Ref - Reference; M - Male; F - Female; Echo-Vega- Echocardiographic Vegetation; Bio - Bioprothesis. 
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Table 7 (Continued) 
 
    
       Case.  Ref.   Date   Age Gender  HIV Stage   Aetiological                  Type        Pre-existing      Valve            Echo-               Surgery     Outcome   
                                                        CD4            Agent                          of Valve   Valvulopathy   involved      Vegetation 
14       54        1992    53        M        No data      Pseudallescheria boydii      Native          No                    Mitral                  Yes                     No                Death 
  
15       25        1991    29        M        199            Enterococcus faecalis           Native         No                    Aortic                   Yes                    No                Survival   
                                                                                                         
16       25        1991    48        M        274            Salmonella enteritis             Native         MS                   Mitral                    Yes                    No                Survival 
 
17       25        1993    51        M        8                Enterococcus faecalis           Native         No                    Aortic                    Yes                    No               Survival 
                                                                                                      
18       25       1995    64         M        5                CN- staphylococci                  Native         No                    Mitral                    Yes                    No              Survival  
 
19       25       1995    43         M        5                Viridians grp streptococci    Native        AS & AR          Aortic                    Yes                    No              Survival 
 
 20      25       1997    29         M       6                 Enterococcus faecalis           Native        No                      Aortic                    Yes                   Yes             Survival  
  
21       25       1999    42         M       118            Coxiella burnettii                   Native        BC Aortic V     Aortic & Mitral    Yes                   Yes             Survival  
 
22       25       1994     44        M       4                MRSA                                      Native        No data             No data                 Not performed  No            Death  
                                                                                                     
23       55       2001     45        M       248            Streptococcus agalactiae       Native        No                     Aortic & Mitral    Yes                    No             Survival    
                                                                                                     
24       1         2003   No data F        413             No data                                     Native        No data            No data                 No data              No data    No data                   
                                                                                                     
25*    38       2006    No          No    Mean          Most common                          Native       No data            Mitral 2                 6 cases               No data    No data  
 ↓                              data         data  138             Staphylococcus aureus                                                      Aortic 4                 Yes                     Yes    
 ↓                                                                                                                                                                   *Others 7  
37*    ″        ″       ″         ″      ″              ″                                         ″           ″                   ″                       ″                   ″            ″ 
 
Ref - Reference; M - Male ; F - Female; Echo-Vega - Echocardiographic Vegetation; MS - Mitral Stenosis; CN-Staphylococci - Coagulase negative staphylococci; grp - group;  
AS & AR -  Aortic Stenosis & Regurgitation; BC Aortic V - Bicuspid aortic valve; MRSA - Methecillin Resistance Staphylococcus aureus.  
 *Not well defined. * Individual characteristic of each case not described in the study.  
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Table 7 (Continued) 
 
 
    
     Case    Ref.    Date     Age       Gender      HIV Stage   Aetiological      Type          Pre-existing      Valve                Echo-          Surgery      Outcome   
                                                                    CD4            Agent              of Valve     Valvulopathy    involved          Vegetation 
 
 
38    59     2005      62              F              79          Aspergillus fumigatus  Native              No data              Mitral                  Yes                        No              Death 
 
38     39     2006       No data       No data     37             No data                      Native             No data             Aortic                No data                Yes             Death         
  
39     39     2006       No data      No data      204           No data                      Native             No data            Aortic                 No data                Yes             Death 
                                                                                                         
40     39     2006      No data       No data      81             No data                      Native             No data            Mitral                 No data                Yes             Death 
 
41     39     2006      No data       No data      868           No data                      Native            No data            No data               No data               Yes             Death  
                                                                                                       
42     39      2006      No data       No data      No data     No data                      No data          No data             No data              No data                Yes             Survival  
 
43     39      2006      No data       No data      438            No data                      No data          No data            No data              No data                Yes             Survival 
 
44     40      1995      No data       No data      No data     No data                       Native          No data           No data               No data                No data       No data                                
 
45     41      1997      No data       No data     No data  Salmonella enteritidis   Native           No data            No data               No data               No data       No data         
                                                                                                      
 
 
        Ref - Reference; M - Male; F - Female; Echo-Vega - Echocardiographic Vegetation 
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CHAPTER FOUR  
 
4.1  DISCUSSION AND LITERATURE  
This study described the clinical profile and outcome of three patients with definitive 
native infective endocarditis, who were infected with HIV and non-intravenous drug 
abusers and who were admitted within a period of two months at the researcher’s 
institution in South Africa.  
 
The literature review in its current form as described in the section 3.2 results of literature 
review and this chapter below; does shed some light on HIV and IE in non-IVDU 
patients, but doesn’t specifically address the issue of the potential co-existence of HIV 
and IE in Africa.   In literature, the experience of infective endocarditis in HIV/AIDS, 
non-intravenous drug abuse appears limited to case reports (attributed to a reported 
relative low prevalence of infective endocarditis in this sub-group of patients), with most 
of these published series of case reports originating outside Africa.²⁵, ⁴² ⁻ ⁵⁵· Surprisingly, 
no case reports published from Africa were found. Instead, all the cases published were 
from prospective observational cohort-studies.¹, ³⁸ - ⁴¹  
 
In a South African prospective observational study (2003), which examined the risk 
factors for infective endocarditis, only 1 (1%) of the cohort of 92 patients was HIV 
seropositive The main risk factors included: rheumatic valve disease (76%); congenital 
heart disease; the presence of prosthetic valves; A history of infective endocarditis and  
HIV infection was not associated with an increased risk of infective endocarditis.¹ In the 
DRC, Longo-Mbenza et al.⁴º, ⁴¹ (1995) reported that: of 83 consecutive HIV-infected 
patients with cardiac disease, only 1.2% had infective endocarditis⁴º; and in 1997 
reported that of 166 HIV-infected patients with heart disease 0.6% developed Salmonella 
enteritidis infectious endocarditis.⁴¹  
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In South Africa, Nel et el.³⁸ (2006, in Durban) reported that of 59 patients with IE, 22% 
(n= 13) were HIV positive in a prospective cohort study. 
Blyth et al.³⁹ (2006), in a prospective cohort study of HIV infected patients undergoing 
cardiac surgery, with or without cardiopulmonary bypass, reported that of 49 patients, 4 
patients (8.2%) had HIV and infective endocarditis.  
 
Given the high prevalence of both HIV and rheumatic valvular heart disease in Africa, a  
cross examining data trend from the above mentioned studies reported from Africa and, 
future prevalence studies may find that a significant proportion of patients with infective 
endocarditis and underlying rheumatic valvular disease are coincidentally HIV infected. 
In this anecdotal report of three cases described, one could extrapolate from these 
numbers to arrive at approximately 10 cases/6 months. If a prospective analysis was 
attempted, with regard to such a retrospective analysis as performed here, there would be 
a substantial number of cases to highlight the clinical importance of the co-existence of 
infective endocarditis and HIV/AIDS in Africa. 
 
The clinical profile, management and outcome observed in these three reported cases are 
discussed below in comparison with similar cases reported in the literature.  
 
4.1.1 Clinical Profile 
The demographic relationship of IE and HIV infection in Africa was depicted from the 
three cases reported: all were young and aged between 23 and 46 years. Similarly, in the 
literature, in the majority of other reported cases outside Africa, the patients were 
relatively young.  
 
It has been described that IE in HIV infected patients can cause a wide variety of 
symptoms, particularly in the earlier stages of infection. Clinical characteristics do not 
differ significantly by HIV serostatus. The disease begins acutely and patients may 
experience such general symptoms as fever, chills, fatigue, weight loss, muscle aches and 
sweating. Fever is the most important and frequent symptom. The mean duration of fever 
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before hospitalization is, in some series, longer in HIV+ patients than in HIV– ones. 
Mean platelets, leukocyte, neutrophil and CD4+ cells counts are significantly higher in 
patients with HIV without AIDS and also in subjects without HIV when compared to 
HIV+ individuals.⁶º, ⁶¹The clinical manifestations depend mainly on the affected valve 
and are different when this varies between either the right or left location. 
 
The clinical course of IE in all three reported cases was acute (<1month). Losa et al.²⁵ in 
Barcelona, Spain, reported a similar observation. The cases presented with acute illness, 
fever in all cases and symptoms of heart failure, which were prominent in Case 2 and 
Case 3, where: there were underlying rheumatic mitral and aortic valvulopathy; both had 
vegetations on the aortic valve. This in comparison with Case 1; who had vegetation on 
the mitral valve and no underlying rheumatic mitral valvulopathy.  
 
The clinical difference in term of morbidity and mortality on either involvement of aortic 
or mitral valve in this sub-group of patients is not well known. However, involvement of 
the aortic valve is a predictor of increased morbidity and mortality in HIV infected 
patients in intravenous drug users with infective endocarditis.³⁵ Valencia Ortega et al.³² 
(1999) generally reported that left-sided endocarditis in HIV infected patients, 
intravenous drug users had increased morbidity and mortality. In HIV-infected patients 
with IE not related to intravenous drug abuse, the mitral and aortic valves are those most 
frequently affected. Losa et al.²⁵ (2003) observed that most cases occur in native valves 
and that the overall mortality rate was not higher than in HIV– patients with IE. 
 
Thromboembolic events were present in all three reported cases, i.e: 
• Case 1 had peripheral arterial embolus and developed pulmonary embolus 
• Case 2 had peripheral arterial embolus  
• Case 3 had peripheral arterial embolus with left atrial appendage thrombus.  
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The development of pulmonary embolus in first case was unusual for left-sided IE, since 
the high rate of pulmonary embolus is common in right-side IE, especially in IVDAs. 
  
In the literature, there was no study found that reported the relationship between 
thrombotic events in HIV infected patient with infective endocarditis. However, in non-
HIV patients, thromboembolic events are a relatively common complication of IE: the 
incidence is high, ranging from 13% - 49% and is a strong predictor of mortality.⁶², ⁶³, ⁶⁴  
The following variables have been accepted as characterizing patients who may have 
increased risk for embolic events:  
 
a)  Morphologic feature of the vegetation: risk for embolic events is closely correlated 
with demonstration of vegetation large enough to be detected by echocardiography and 
the vegetation size as a predictor for embolic complication is controversial.⁶², ⁶⁵ However, 
there is a significant correlation between large vegetation and thromboembolic events: 
patients with embolic events have significantly larger vegetations than those without 
embolic events.⁶⁵, -⁶⁶, ⁶⁷ Moreover, when vegetation size if greater than or equal to 10mm, 
particularly if the native valve is involved, mobility and low density vegetations at initial 
echocardiography have been suggested to have a prognostic implication.⁶⁸, ⁶⁹, ⁷º 
 
b)  Site of infection: a high incidence of embolic complications has been observed in 
native mitral when compared to aortic valve endocarditis.⁶²  
 
c)  Causative organism: there is no consensus. However, most published series report 2 
- 3 times higher frequency of embolic complication in IE due to Enterococci, Abiotrophic 
spp, fastidious gram negative bacteria - HACEK and fungi, when compared to 
streptococci.⁶², ⁷¹  
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d)  Duration since onset of the infection: It has established that the hazard for embolic 
events peaks at the beginning of IE, often before hospital admission ends or before or 
within the first two weeks of initiation of antimicrobial therapy.⁶², ⁷¹ It has been 
established that it is not only the vegetation size and morphologic characteristics, the site 
of infection, the causative organism and the relative duration onset of IE and initiation 
antimicrobial therapy that predicts thromboembolic events. Inflammation-induced 
procoagulant changes and alterations in platelet activity appear to play an important role 
in thromboembolic complications of infective endocarditis.⁶³, ⁶⁴, ⁶⁶, ⁶⁷, ⁷², ⁷³    
 
The IE patients with thrombotic events have increased systemic coagulation activation, 
enhanced platelet activity / damage and impaired fibrinolysis - as evidenced by increased 
plasma levels of prothrombin fragment 1 and 2, thrombin–antithrombin III complex, 
plasminogen activator inhibitor-1, β-thromboglobulin and platelet factor 4 -  than do 
those without embolic event.⁶⁶, ⁶⁷  
 
Infection-associated elevated antiphosholipid antibodies levels in patients with infective 
endocarditis may contribute to the increased risk for major embolic events in these 
patients.⁷² On the other hand, thrombotic events in patients infected with HIV, when  
compared to the general population, is relatively high.⁷⁴, ⁷⁵, ⁷⁶,⁷⁷  
 
Studies have shown that: 
• HIV irritates endothelial cells and disrupts storage and excretion of the Von 
Willebrand factor and tumour necrotic factor-α. .⁷⁴, ⁷⁵, ⁷⁶,⁷⁷ 
• Pro-inflammatory cytokines increases the expression of plasminogen activator 
inhibitor-1 in endothelial cells.⁷⁴, ⁷⁵, ⁷⁶,⁷⁷ 
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• The presence of a persistent or transient autoantibody to phospholipids, including 
lupus anticoagulant and anticardiolipin, diminishes the levels of anticoagulant 
proteins, protein C, protein S and antithrombin III. .⁷⁴, ⁷⁵, ⁷⁶,⁷⁷ 
• Elevated levels of factor VIII and homocysteine may contribute to increased 
thrombotic events in HIV patients.⁷⁵, ⁷⁶  
 
It is unknown whether the HIV infection has an additive contribution to thromboembolic 
complications to already pre-existing pro-thrombotic milieu in patients with infective 
endocarditis. Future prospective studies may describe and characterize the 
thromboembolic events in HIV patients with IE.  
 
4.1.2  Pathogens of infective endocarditis in HIV patients, non-intravenous drug  
 abuse   
 Identification of the causative agent is a very important piece of information in the 
management of IE and has a positive implication on the morbidity and mortality. Blood 
cultures with negative endocarditis often delay diagnosis and the start of treatment - with 
a profound impact on the clinical outcome.¹⁸, ⁶²  
 
In this study, in all three cases, no causative organism was isolated. It was established 
that at least three blood samples were taken from each case, but it was not established 
whether the samples were labelled suspected / query IE or prolonged incubation period of 
more than six days or special culture conditions were performed to try to isolate those 
organisms requiring special culture. Spach et al., ⁵º in their case report, illustrated the 
value of prolonged incubation of blood cultures in an attempt to isolate fastidious 
organisms. Moreover, they emphasized the need for communication between clinicians 
and microbiologists to ensure that the necessary steps are taken in order to isolate 
fastidious organisms such as Rochalimaea quintana (Bartonella quintana).   
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Koegelenberg et al.¹ (2003, in Cape Town) reported a high frequency of culture negative 
endocarditis 20.5% (8/39 cases). Valencia Ortega et al.³² (1999) reported culture negative 
endocarditis in 62% of 34 cases of left-sided endocarditis – most of whom were IVDAs 
and notably severe immunosuppressed.  
 
In this latter study, among 46 reported cases of IE in HIV, non-IVDA culture positive 
endocarditis was reported in 37 cases (80%). A wide etiologic range was reported, as 
shown in Table 7 above (see Chapter 3).²⁵, ³⁸, ⁴¹ ⁻ ⁵⁴, ⁵⁹· The bacterial endocarditis 
included:  
• Staphylococcus aureus 
• Staphylococcus epidermiditis 
• Salmonella species 
• streptococcus pneumoniae 
• Streptococcus agalactiae streptococcus viridians 
• Haemophilus influenzae 
• Enterococcus faecalis 
• Viridians group streptococci 
• Streptococcus agalactiae  
• Listeria monocytogenes 
• Bartonella quintana 
• Coxiella burnettii 
• Coagulase negative staphylococci.  
 
The fungi endocarditis the pathogens reported included: 
• Candida albicans 
• Candida zeylanoides 
• Cryptococcus neoformans 
• Aspergillus fumigatus  
• Pseudallescheria boydii.  
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In addition, polymicrobial pathogens were described in the case reports. This reflects 
different clinical and environmental conditions in which these studies – the compiled 
series of case reports - were undertaken. However Staphylococcus aureus was the most 
common etiologic agent reported in these case reports.  
 
The frequency of negative blood culture endocarditis in HIV, non-IVDAs in Africa is not 
well characterized, nor described in literature. The reported frequency of culture negative 
in non-HIV IE ranges from 5% to 14% and is commonly attributed by previous 
administration of antibiotics. It may also be associated with fastidious pathogens, 
including:  
• Legionella 
• Coxiella, Bartonella species 
• the HACEK group (Haemophilus species, Actinobacillus actinomycetecomitants, 
Cardiobacterium hominis, Eikinella corrodens and Kiengella kingae) 
• fungi such as Candida, Histoplasma 
• Aspergillus species, which are difficult to culture.¹⁸, ⁷⁸, ⁷⁹  
 
Beynon et al.¹⁸ suggested serological testing can be particularly useful for investigating 
the possibility of Coxiella burnetti (Q fever) and Bartonella infection, and that this 
should be done in all patients who are initially culture negative. The advent of molecular 
techniques, notably polymerase chain reaction, definitely has a place in the detection of 
fastidious and non-culturable agents in this sub-group of patients.⁸º  
 
Although obtaining a good microbiological result is difficult in IE, the compilation of 
other case reports clearly show that causative agents can be identified in many cases; 
there is no specific reason why that should not be possible in our setting, if one could 
follow the framework of the laboratory diagnosis of common organisms associated with 
culture negative endocarditis. See Table 8 below, which is well described. 
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Table 8: Laboratory Diagnosis of Common Causes of Culture Negative Endocarditis  
 
 
  Organism                                                                                     Approach  
Abiotrophia species (previously classified as nutritionally               Grow in thioglycolate medium of blood culture and as satellite colonies around  
Variant streptococci)                                                                           Staphylococcus aureus on blood agar or on medium supplemented with pyridoxal  
                                                                                                           Hydrochloride or L – cysteine. 
 
Bartonella species (usually Bartonella henselae or B. quintana)     Serologic tests. 
                                                                                                           Lysis-centrifugation system for blood cultures. 
                                                                                                           PCR of valve or embolized vegetations⁸¹, ⁸², ⁸³; special culture techniques available, but organisms are slow  
                                                                                                            growing and may require a month or more for isolation. 
 
Coxiella burnetii (Q fever)                                                                Serologic tests. 
                                                                                                           PCR, Giemsa stain, or immunohistologic techniques on operative specimens. 
 
HACEK organisms                                                                           Blood cultures positive by day 7; occasionally require prolonged incubation and sub-culturing. 
 
Chlamydia species (usually Chlamydia psittaci)                              Culture from blood has been described. 
                                                                                                           Serologic tests. 
                                                                                                           Direct staining of tissue with use of fluorescent monoclonal antibody. 
 
Tropheryma whipplei                                                                        Histologic examination (silver and PAS stains) of excised heart valve; PCR26 or culture of vegetation. 
 
Legionella species                                                                             Sub-culture from blood cultures, lysis-centrifugation pellet from blood cultures, or  
                                                                                                             operative specimens on BCYE agar; direct detection on heart valves with fluorescent antibody.                                                            
                                                                                                           Serologic test. 
 
Brucella species (usually Brucella melitensis or B. abortus)            Serologic tests. 
                                                                                                           Prolonged incubation of standard or lysis-centrifugation blood cultures. 
 
Fungi                                                                                                 Regular blood cultures often positive for candida species; lysis-centrifugation system with   
                                                                                                           specific fungal medium can increase yield; testing urine for Histoplasma capsulatum antigen  
                                                                                                           or serum for Cryptococcus neoformans polysaccharide capsular antigen can be helpful. 
                                                                                                          Accessible lesions (such as emboli) should be cultured and examined histologically                                                                                
for fungi                                                                                                             
*PCR denotes polymerase chain reaction; HACEK organisms - haemophilus species (Haemophilus parainfluenzae, H. aphrophilus, and H. paraphrophilus), Actinobacillus 
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae; PAS - periodic acid–Schiff; BCYE - buffered charcoal yeast extract.
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4.1.3  Antimicrobial treatments standard for IE in HIV 
The standard antimicrobial treatment of IE in HIV, non-IVDAs is not well established in 
literature. Likewise the antimicrobial therapy of IE in IVDAs HIV positive patients is not 
fully established.⁶² However, the most important advance in antibiotic therapy is that non-
complicated S. aureus right-sided endocarditis can be successfully treated with an 
intravenous 2-week course of nafcillin or cloxacillin plus an aminoglycoside, although the 
aminoglycoside administration could probably be stopped after the first 3 to 5 days once a 
two-week course has been suggested.²¹, ⁶¹ Fowler et al.⁸⁴ (2006) have shown that 
daptomycin is not inferior therapy to standard therapy for the treatment of S. aureus 
bacteremia and right-sided endocarditis caused by MSSA or MRSA. Daptomycin may be 
considered an alternative to vancomycin where clinical failure or resistance to 
vancomycin is reported. However the number of HIV positive patients in this study was 
relatively small.  
 
The choice and length of treatment are dictated by the pathogen isolated from cultures 
and require the close collaboration of a microbiologist and physician. However, in 
clinical practice, the initiation of antimicrobial treatment doesn’t wait for culture results. 
Therefore, the empiric treatment: should be started as soon, as appropriate; it should  
always cover the most common isolated organisms in the locality, depending on the 
suspected microorganisms, site in the heart and specific clinical characteristics of the 
patient. Some authors⁶², ⁷⁸, ⁸⁵, ⁸⁶ suggest empiric treatment should consist of vancomycin 
and gentamicin or penicillinase-resistant penicillin or/and vancomycin, gentamicin and 
cloxacillin. Vancomycin is less preferred as empiric therapy due to potential 
nephrotoxicity, especially when combined with gentamicin and a growing concern of 
increasing resistance to vancomycin. When culture and sensitivity results are obtained, 
appropriate antimicrobial treatment should be instituted. Delaying appropriate therapeutic 
measures whilst waiting for culture is unacceptable and is associated with increased 
mortality.², ⁶²  
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In all three cases reported in this study, empiric therapy was initiated consisting of 
penicillin, cloxacillin and gentamicin for first and second case. On re-admission, the 
second case was treated with ceftriaxone, cloxacillin and vancomycin, after isolating 
coagulase negative staphylococcus sensitive to cloxacillin and vancomycin in single set 
of culture. In the third case, the treatment included ceftriaxone, gentamicin and 
cloxacillin. The empiric therapy combination given was intended to cover the most 
common isolates in the setting (Staphylococcus aureus and Streptococcal viridians).  
 
In non-HIV, the most common causes of infective endocarditis and their treatments are 
summarized in Table 9 below. Prolonged parenteral administration of a bactericidal 
antimicrobial agent or combination of agents is currently recommended.⁷⁸, ⁸⁵, ⁸⁶  
 
4.1.4.  Surgical management of IE in HIV. Does IE influence surgery results? 
Surgery during active IE in non-HIV patients has significantly contributed to prognostic 
improvement during the last decade.⁶² The combined medical and surgical therapy for 
infective endocarditis can decrease mortality among patients who have congestive heart 
failure, perivalvular invasive disease, or uncontrolled infection despite maximal 
antimicrobial therapy. Congestive heart failure is the strongest indication for surgery in 
infective endocarditis. For example, medically treated patients with moderate-to-severe 
congestive heart failure due to endocarditis-related valvular dysfunction have a mortality 
rate of 56 to 86 percent, compared with 11 to 35 percent among patients treated with 
combined medical and surgical therapy.²  
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Table 9: Usual antimicrobial therapies for common causes of infective endocarditis  
PATHOGEN                               NATIVE-VALVE ENDOCARDITIS                                                       PROSTHETIC-VALVE ENDOCARDITIS    
                         
                                                 ANTIMICROBIAL THERAPY                 COMMENTS                                        ANTIMICROBIAL THERAPY                   COMMENTS   
 
1. Penicillin-susceptible viridans  Penicillin G or ceftriaxone             A 2-wk regimen of penicillin G (or ceftriaxone)                        Penicillin G for 6 wk                 Shorter duration of treatment with 
streptococci, Streptococcus         for 4 wk  †                                     and gentamicin can be used some cases,⁸⁷ ⁸⁸                 and gentamicin                                          an aminoglycoside (2 wk) is usually  
bovis streptococci with MIC                                                               but not recommended for patients with myocardial                           for 2 wk                                                         appropriate  for prosthetic valve                                                                                                                 
of penicillin  0.1 μg/ml                                                                       extra cardiac foci of infection or prosthetic valve                                                                      endocarditis due to penicillin susceptible 
                                                                                                          endocarditis                                                                                                                              viridans streptococci, S bovis, or other         
                                                                                                                                                                                streptococci with MIC of penicillin ≤0.1µg 
2. Relatively penicillin-resistant   Penicillin G for 4 wk   and                                                                                                               Penicillin G for 6 wk 
streptococci (MIC                        gentamicin for 2 wk†                                                                                                                       and gentamicin  
of penicillin >0.1 to                                                                                                                                                                              for 4 wk†      
0.5 μg/ml) 
 
3. Streptococcus species with    Penicillin G (or ampicillin)              6 wk of therapy is recommended for patients                           Penicillin G  
MIC of penicillin >0.5                  and gentamicin or 4–6 wk†           with symptoms lasting longer than 3 mo,                                  (or ampicillin)   
μg/ml, enterococcus                                                                         myocardial abscess, or selected  other                                     and gentamicin 
species, or abiotrophia                                                                     complications                                                                            for 6 wk† 
species 
 
4. Methicillin-susceptible            Nafcillin or oxacillin for 4–6 wk,     In the few patients infected with a penicillin                           Nafcillin or oxacillin with           It may be prudent to delay initiation 
Staphylococci                             with or without addition of             susceptible staphylococcus, penicillin G may                          rifampin  for 6 wk and              of rifampin for 1 or 2 days, until therapy 
                                                   Gentamicin for the first 3-5 days    be used instead of nafcillin or oxacillin.                                    gentamicin for 2 wk‡               with two other effective antistaphylococcal 
                                                    of therapy‡                                                                                                                                                                                     drugs has been initiated. 
5. Methicillin-resistant                 Vancomycin, with or without                                                                                                           Vancomycin with rifampin       If the staphylococcus is resistant to gentamicin, 
Staphylococci                              addition of gentamicin, for                                                                                                              for 6 wk and gentamicin          an alternative third agent should be chosen 
                                                    the first 3–5 days of therapy                                                                                                           for 2 wk                                   on the basis of in vitro susceptibility 
6. Right-sided staphylococcal     Nafcillin or oxacillin with                This 2-wk regimen has been studied for infections due to 
native-valve endocarditis            gentamicin for 2 wk                        aminoglycoside- susceptible isolate. Exclusions to short  
in selected patients                                                                           course therapy include any cardiac or extracardiac 
                                                                          complications associated with infective endocarditis, 
                                                                          persistence of fever for 7 days or more, and infection with 
                                                                                                         HIV. Patients with vegetations greater than 1–2 cm according 
                                                                          to echocardiography should probably be excluded from short  
                                                                          course therapy.75-77 
7. HACEK organisms                 Ceftriaxone for 4 wk                      Ampicillin and gentamicin for 4 wk is an alternative regimen,   Ceftriaxone for 6 wk          Ampicillin and gentamicin for 6 wk is an  
                                                                          but some isolates may produce beta-lactamase, thereby                                                        alternative regimen, but some isolates 
                                                                          reducing the efficacy of this regimen.                                                                                       may produce beta-lactamase,  thereby 
                                                                                                                                                                                                                                                           reducing the efficacy of this regimen. 
*Data are from Bayer et al.,⁷⁸ Working Party of the British Society for Antimicrobial Chemotherapy,⁸⁵ and Wilson et al.⁸⁶ MIC denotes minimal inhibitory concentration; HACEK organisms - haemophilus 
species (Haemophilus parainfluenzae, H. aphrophilus, and H. paraphrophilus), Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae; HIV - human 
immunodeficiency virus. †Vancomycin therapy is indicated for patients with confirmed immediate hypersensitivity reactions to beta-lactam antibiotics. ‡For patients who have infective endocarditis due to 
methicillin-susceptible staphylococci and who are allergic to penicillins, a first-generation cephalosporin or vancomycin can be substituted for nafcillin or oxacillin. Cephalosporins 
should be avoided in patients with confirmed immediate-type hypersensitivity reactions to beta-lactam antibiotics.
 Surgery is also indicated in active native IE patients with:  
• acute aortic or mitral regurgitation, especially when associated with congestive 
heart failure 
• evidence of peri and para-valvular extension (locally uncontrolled infection) 
• persistent infection after 7 - 10days of adequate antibiotic therapy, pointing to a 
failure of therapy of conservative management 
• infection due to microorganisms with poor response to antibiotics therapy (fungi, 
Brucella species, Coxiella species, Staphylococcus lugdunensis, Enteroccocus 
species) with a high level of resistance to gentamicin and gram negative 
organisms 
• mobile large vegetation (> 10mm – 15mm in size) before or after the first week of 
antibiotic therapy, especially when there is an increase in size despite antibiotic 
therapy and which represents mitral kissing vegetation 
• recurrent emboli, despite appropriate antibiotics therapy 
• obstructive vegetation.⁶²    
 
The beneficial effect of surgery versus medical treatment has been demonstrated, despite 
a higher perioperative mortality associated with surgery for PVE than NVE. Surgery for 
active PVE should be considered in:  
• early PVE,⁸⁹, ⁹¹   
• late PVE complicated by prosthetic valve dysfunction, including perivalvular 
leaks, persistent blood culture, abscess formation, conduction abnormalities, or 
large vegetation, particularly when left-sided valves are involved and 
Staphylococci are the infecting agent.⁹º - ⁹³  
 
HIV-infected patients with active IE who needed surgery, as indicated above, and who 
underwent surgery, have shown to achieve good results, at least in the short term.²⁹, ³⁸, ³⁹, 
⁴⁶, ⁵º, ⁵² Good outcome has been reported with the use of mechanical heart valves, 
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bioprosthetic valves and homografts5 in patients who have endocarditis in this sub-group of 
patients.⁹⁴ Cardiac surgery in HIV-infected patients with IE does not worsen the prognosis.²⁹, 
³⁵, ⁹⁵ Nor does the cardiopulmonary by-pass (CPB) seem to accelerate immunodeficiency or 
to produce adverse effects on patients with HIV- infection.³⁹, ⁹⁶, ⁹⁷ However, high mortality 
has been reported in patients with severe immunosuppression   
(CD⁺ cell count less than 200cells/µl) or with AIDS and left-sided IE in IVDAs. ⁹⁴, ⁹⁵, ⁹⁸ 
Miro et al.⁹⁵ indicated that in IVDAs with right-sided IE, the overall mortality with 
surgery is less than 2%. In contrast, the prognosis of left-sided IE is less favourable with 
surgery in IVDAs - it is 15% to 25%. No data on surgical management for HIV infected 
patients with non-IVDAs was found in the literature.  
 
In this study, the compiled series of case reports demonstrated that 11 cases underwent 
surgery, seven had a good outcome, but 4 died. In the cases reported here: 
• Case1 and Case 2 had absolute indications for surgical management. Case1 had a 
large mobile vegetation ~22cm on the anterior mitral valve leaflet flopping into 
the left atrium, with acute mitral regurgitation and features of heart failure. 
Moreover, Case 1 developed haemodynamic instability within 24 hours of 
intravenous antibiotics.  
• Case 2 had biventricular heart failure and chronic underlying rheumatic mitral and 
aortic valvulopathy associated with moderate to severe mitral regurgitation and 
severe aortic regurgitation on admission. Despite being on antibiotics for eight 
days, Case 2 had persistent infection (persistent fever) associated with refractory 
heart failure, haemodynamic instability and worsened renal dysfunction.  
 
Both Case 1 and Case 2 had CD 4⁺ more than 200/μl.  
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Blyth et al.³⁹ (2006, in South Africa) reported an early higher mortality rate in a series of 
a small group than in uninfected patients. Out of six emergency valve replacements, 
carried out according to the major indicators of haemodynamic and infective 
compromise, four died within three months - two of these with CD4⁺ counts of 37 and 
204/μl, respectively - from apparent ongoing or recurrent infections. A third, with a CD4⁺ 
count of 81μ/l, died at three months after complaining of dyspnoea. The fourth, with a 
CD4⁺ count of 868/μl, died on day 13, possibly with tamponade. Two survived: one with 
an unknown CD4⁺ cell count, lost to follow up; the other (with a count of 438/μl) was 
well more than five years later. In this small series, it would be difficult to discount the 
degree of immune compromise in the outcome of the patients with low CD4⁺ cell counts 
of 37 and 204/μl. It would have been expected that the surgical therapy could have 
changed the outcome of these two cases.         
 
4.1.4  Relationship between immune status and clinical course of patients with IE 
and HIV  
Healthy adults have CD4⁺ cell counts ranging from 500 to 1450 cells/µl. In HIV 
individuals with counts more than 500, their immune system is less unaffected, but when 
this is less than 500cells/µl, it means that the immune system is damaged. If the CD4⁺ 
count is below 200cells/µl, it means that HIV has progressed to AIDS. It has been 
confirmed that there is a strong relation between HIV-RNA levels and disease stage or 
CD4⁺ levels.  
 
It is not clearly defined whether HIV infection is responsible for the worst evolution of IE in 
HIV infected patients. However, in IVDAs, the clinical outcome of these patients depends on 
the affected valve and the cultured organisms, rather than on the HIV serostatus. HIV 
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infection has shown to not affect the clinical manifestations or evolution of IE. The 
presence of AIDS or CD4⁺ lymphocytes below 200cells/µl predicts the worst prognosis ⁶¹   
 
In HIV non-IVDAs, data available are only limited to series of case reports. In this 
compiled series of case reports:  
• the mean CD4⁺ count was 161cells/µl ranging from 4-922cells/µl among 36 
known CD4⁺ cases 
• in 9 cases, the CD4⁺ counts were not reported 
• two cases had CD4⁺ more than 500cells/µl, one (with counts of 868cells/µl) died 
and the other case (with counts of 922 cells/µl) survived 
• in the majority, the CD4⁺ was less than 500cells/µl and where the clinical 
outcome was reported, four out of five (with a count less than 500cells/µl but 
more 200 cells/µl) survived and eight out of thirteen (with a count less than 
200cells/µl) survived.      
 
4.1.5  Complication of IE in HIV patients  
The complications of IE in HIV positive, non-intravenous drug user patients are not well 
described nor well defined.²⁵, ³⁸ Nel et al.²⁵ (2006, in Durban) observed, in a small series 
of cases, a higher prevalence of perivalvular complication - aortic root abscess - in HIV 
positive IE than in HIV negative; this was related to the compromised immune status. The 
role of immunosuppression on root abscess formation is not yet established. However, it 
is well known that bacterial invasion at the periannular level causes tissue weakening, 
necrosis and subsequent formation of periannular complications. Once established, 
periannular abscesses place the patient at increased risk for adverse outcomes, including 
heart failure, requirement for surgery, and death.  
 
In the cases reported in this study, Case 2 was suspected to have aortic root abscess on 
transthoracic echocardiography examination, but this was not confirmed on 
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transoesophageal echocardiography, which has high sensitivity and specificity (80 - 
90%).⁹⁹ The MRI that was performed revealed no aortic root abscess. However, the 
sensitivity and specificity of MRI on aortic root abscess is not well defined. ¹ºº, ¹º¹  
 
Disseminated intravascular coagulopathy was observed in the first case, on admission, 
based on thrombocytopenia and prolonged prothrombin time, which improved during the 
course of treatment. However, thrombocytopenia could have been associated with HIV 
status⁷⁴. It is less likely that prolonged prothrombin time could have been triggered by an 
auto-anticoagulation phenomenon in the presence of arterial thrombus, due to the 
background of normal liver functions. A further complication described in the first case 
was pulmonary embolus (which is unusual for left-sided endocarditis), based on 
echocardiographic findings that revealed increased pulmonary arterial pressure of 
76mmHg. Unfortunately, the pulmonary embolus was not confirmed as the patient died 
soon after.  
 
Case 3 also had thrombotic complications, presenting with arterial and left atrial 
appendage thrombus. It is unknown whether the HIV infection has an additive 
contribution to thromboembolic complications, on already pre existing pro-thrombotic 
milieu, in patients with infective endocarditis.  
 
Renal dysfunction was observed in Case 2 and Case 3, the causation of which may have 
been multifactorial, e.g. reduced renal perfusion complicated by haemodynamic 
instability, immunological complication of IE glomeronephritis, nephrotoxic agent 
antibiotics administered (gentamicin and vancomycin) and/or HIV related nephropathy.     
 
Systemic complications are more frequent in left-sided endocarditis and the need for 
surgical treatment is more than ten times that observed in right-sided endocarditis¹º²,¹º³ In 
IVDAs with HIV infection, complications are quite different if patients have right-sided 
or left-sided IE. The most important complications are:  
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• congestive heart failure (30%) 
• renal failure (35%) 
• major systemic emboli that often involve a major arterial bed, including coronary 
arteries, the spleen, the central nervous system, the bowel and extremities. 
 
Congestive heart failure (CHF) has the greatest impact on prognosis and occurs more 
frequently in aortic valve infections (30%) than with mitral (20%) or tricuspid disease 
(8%).⁶² CHF most likely to complicate left-sided IE may develop acutely from the 
perforation of a valve leaflet, rupture of infected chordae or valve obstruction from bulky 
vegetations. It may also develop more insidiously, despite antibiotics, as a result of a 
progressive worsening of valvular insufficiency and ventricular dysfunction. In IVDAs 
Ribera et al.²⁷ found a statistical significance between HIV+ and HIV– patients in regard 
to CHF (15.7 vs. 32.8%), renal failure (19.9 vs. 37.3%) and surgical treatment (7.4 vs. 
23.9%).  
 
4.1.6 Clinical outcome of HIV positive patients with IE 
It is well known that, if untreated, IE is a fatal disease, even in HIV negative patients. 
Major diagnostic advances and therapeutic progress has contributed to some prognostic 
improvements during the last few decades. Differences in morbidity and mortality 
recently reported point to the importance of an early and proper diagnosis and adequate 
treatment.  
 
Successful management requires a multidisciplinary approach involving microbiologists, 
cardiologists and cardiothoracic surgeons.², ¹⁶, ¹⁷, ¹⁸, ⁶², ¹º⁴ The morbidity and mortality of 
infective endocarditis in HIV positive non-intravenous drug abuse patients is not well 
characterized or defined. Studies reported in the literature are limited to a series of case 
reports.²⁵, ⁴² ⁻ ⁵⁵, ⁵⁹ 
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It is unfortunate that the outcome of all three cases in the study reported here were 
disappointing. The high mortality in this study could have been contributed to by an 
inadequate therapeutic approach. Urgent cardiac surgery could have changed the outcome 
of Case 2 and Case 3, who both had absolute indications for surgical intervention. Case 1 
had large mobile vegetation ~22cm on the anterior mitral valve leaflet flopping into the 
left atrium, with acute mitral regurgitation and features of heart failure, as well as 
developed haemodynamic instability within 24 hours of intravenous antibiotics. Case 2 
had: biventricular heart failure on a background of chronic underlying rheumatic mitral 
and aortic valvulopathy, associated with moderate to severe mitral regurgitation and 
severe aortic regurgitation on admission; persistent infection, despite being on antibiotics 
for eight days (persistent fever), haemodynamic instability and worsened renal 
dysfunction. Both cases had CD4⁺ more than 200/μl. Surgical intervention would have 
been appropriate. Case 3 had no absolute indication for surgical treatment, but was 
severely immunocompromised with a CD4⁺ count of 67cells/μl.    
 
In IVDAs, the prognosis is good, with a mortality rate between 5 and 10%, when the 
tricuspid valve is involved and caused by S. aureus. When the left side is affected, the 
diagnosis is more difficult and mortality increases to more than 15 to 18%. Although, in 
general, HIV infection does not affect the clinical manifestations or evolution of IE, the 
presence of AIDS or CD4+ lymphocytes below 200cells/µl predicts a worse prognosis. 
Cardiac surgery is not usually necessary, except in complicated left-sided IE; fungal 
disease does not worsen the prognosis.², ¹⁶, ³⁵, ⁹⁵, ¹⁰⁵  
 
Nahass et al.³⁶ found that the mortality was higher in patients with symptomatic HIV 
disease. Valencia et al.¹º⁶ found a similar rate of mortality in patients with and without 
HIV infection. Pulvirenti et al.³⁷ reported that IE in IVDAs with HIV infection had a 
differing outcome, depending on the degree of immunosuppression, and that higher 
mortality rates correlated with lower CD4+ cell counts. Ribera et al. ²⁷ in a prospective 
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study in 1998 observed that outcome was similar relative to HIV serostatus, but mortality 
was higher in severely immunosuppressed patients and in those with mixed or left-sided 
involvement. Cicalini ET al.³¹ reviewed 108 episodes of IE in 105 patients with HIV 
infection and also observed that severe immunosuppresion and left-sided valvular 
involvement are associated with a greater risk of mortality. 
 
4.2 CONCLUSION AND PERSPECTIVE 
The clinical pattern of IE in HIV positive patients who are not IVDAs is not well 
described in literature. However, in this anecdotal case report, the three retrospectively 
studied patients had a poor outcome. Given the high prevalence of both HIV/AIDS and 
rheumatic valvular heart disease in Africa, in future, we are more likely to see a 
significant proportion of patients with IE and underlying rheumatic valvular heart disease 
who are coincidentally HIV infected.  
 
Based on this anecdotal report of three cases described, if an extrapolation was done from 
these numbers, the result provided would be approximately 10 cases/6 months. If a 
prospective analysis could be attempted with regard to such a retrospective analysis of 
this anecdotal case report as performed here, there would be a substantial number of 
cases to highlight the clinical importance of the co-existence of infective endocarditis and 
HIV/AIDS in Africa. The literature review in its current form may shed some light on 
HIV and IE in non-IVDU patients, but doesn’t specifically address the issue of the 
potential co-existence of HIV and IE in Africa.   There is a useful need for prospective 
studies describing the prevalence and outcome and for subsequently defining 
management of this condition in Africa. 
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